The Anti-inflammatory TIPE2 Is an Inhibitor of the Oncogenic Ras

SummaryThe connection between cancer and inflammation is widely recognized, yet the underlying molecular mechanisms are poorly understood. We report here that TIPE2 provides a molecular bridge from inflammation to cancer by targeting the Ras signaling pathway. TIPE2 binds the Ras-interacting domain of the RalGDS family of proteins, which are essential effectors of activated Ras. This binding prevented Ras from forming an active complex, thereby inhibiting the activation of the downstream signaling molecules Ral and AKT. Consequently, TIPE2 deficiency led to heightened activation of Ral and AKT, resistance to cell death, increased migration, and dysregulation of exocyst complex formation. Conversely, TIPE2 overexpression induced cell death and significantly inhibited Ras-induced tumorigenesis in mice. Importantly, TIPE2 expression was either completely lost or significantly downregulated in human hepatic cancer. Thus, TIPE2 is an inhibitor of both inflammation and cancer, and a potential drug target for inflammatory and neoplastic diseases.

► TIPE2 links inflammation to cancer by targeting the Ras signaling pathway
► TIPE2 prevents Ras from binding the Ras-interacting domain of RGL
► TIPE2 suppresses Ras-induced tumorigenesis in vivo
► TIPE2 expression is significantly downregulated in human hepatic cancer